Dianthus Therapeutics Inc (NAS:DNTH)
$ 22.55 0.81 (3.73%) Market Cap: 661.83 Mil Enterprise Value: 261.52 Mil PE Ratio: 0 PB Ratio: 1.71 GF Score: 20/100

Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 08:40PM GMT
Kyuwon Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Hi, everyone. Thank you for joining us on -- here on day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. I'm Paul Choi, and I cover the smid cap biotechnology sector here at the firm. Our next session will be with Magenta, and joining us from the company is CEO, Jason Gardner. (Operator Instructions)

And with that, I'll turn it over to Jason for some opening comments and an overview of Magenta. Jason?

Jason Gardner
Magenta Therapeutics, Inc. - Co-Founder, CEO, President & Director

Great. Well, first of all, thank you, Paul, and the Goldman team for the opportunity to participate in the Goldman conference this year. I'd also like to thank the Magentini, all of our partners, our investors and the patients and their families for their commitment to our vision. And we've made terrific progress this year.

So let me just begin by framing Magenta as a company. We are the only stem cell transplant-focused platform biotech. We have 2 programs that are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot